SEPN

Septerna, Inc. NASDAQ Listed Oct 25, 2024

Healthcare ·Biotechnology ·US · septerna.com

$23.98

Mkt Cap $1.1B

52w Low $6.44 67.0% of range 52w High $32.63

50d MA $25.49 200d MA $22.13

P/E (TTM) -21.5x

EV/EBITDA -14.4x

P/B 2.7x

Debt/Equity 0.1x

ROE -12.8%

P/FCF 11.3x

RSI (14) —

ATR (14) —

Beta 3.50

50d MA $25.49

200d MA $22.13

Avg Volume 319.6K

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.

SIC Code

2834

CIK (SEC)

1984086

Phone

650 338 3533

250 East Grand Avenue · South San Francisco, CA 94080 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 9, 2026	AMC	-0.23	-0.24	-4.3%	29.06	+1.2%	-3.6%	-9.5%	-9.0%	-13.5%	-13.5%	—
Nov 10, 2025	AMC	0.19	-0.09	-147.4%	18.10	+1.3%	+6.3%	+6.2%	+6.3%	+28.6%	+19.6%	—
Aug 11, 2025	AMC	-0.05	-0.56	-1020.0%	11.49	-4.3%	-2.5%	+1.7%	+1.7%	+2.0%	+0.9%	—
May 15, 2025	AMC	-0.38	-0.49	-28.9%	10.12	+4.4%	-2.8%	-1.5%	-6.9%	-10.5%	-6.3%	—
Mar 27, 2025	AMC	-0.69	-0.64	+7.2%	6.29	-5.7%	-3.0%	-7.9%	-20.2%	-12.7%	-7.8%	—
Nov 21, 2024	AMC	-0.83	-8.40	-912.0%	21.79	-0.9%	+1.0%	+6.7%	+11.4%	+13.7%	+16.1%	—
Dec 31, 2023	AMC	—	2.05	—	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	—	-0.56	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
May 1	Stifel	Initiates	Buy	$43	$23.76	$23.84	+0.3%	-0.6%	—	—	—	—
Apr 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.34	$23.57	+1.0%	+3.4%	+11.1%	+7.1%	+12.0%	+15.1%
Mar 24	JP Morgan	Maintains	Overweight → Overweight	—	$23.78	$23.77	-0.0%	-1.4%	+1.8%	+4.0%	+0.4%	-2.0%
Mar 11	Truist	Maintains	Buy → Buy	—	$28.02	$27.45	-2.0%	-6.1%	-5.6%	-10.3%	-10.3%	-10.2%
Mar 3	Wells Fargo	Maintains	Overweight → Overweight	—	$28.64	$28.51	-0.5%	-1.8%	+0.7%	-4.1%	+0.5%	+1.5%
Mar 2	HC Wainwright& Co.	Maintains	Buy → Buy	—	$29.02	$28.11	-3.1%	-1.3%	-3.1%	-0.7%	-5.3%	-0.8%
Mar 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$29.02	$28.11	-3.1%	-1.3%	-3.1%	-0.7%	-5.3%	-0.8%
Jan 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.07	$26.37	+1.2%	+3.7%	+1.1%	+2.3%	-1.2%	-0.4%
Nov 14	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$19.24	$19.69	+2.3%	+20.9%	+12.5%	+12.7%	+20.1%	+23.5%
Nov 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.10	$18.34	+1.3%	+6.3%	+6.2%	+6.3%	+28.6%	+19.6%
Sep 5	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$14.12	$14.35	+1.6%	+2.2%	+3.9%	+7.8%	+4.2%	+2.1%
Aug 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.09	$11.08	-0.1%	+5.5%	+8.1%	+7.8%	+14.5%	+13.9%
May 16	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$10.12	$10.57	+4.4%	-2.8%	-1.5%	-6.9%	-10.5%	-6.3%
May 16	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$10.12	$10.57	+4.4%	-2.8%	-1.5%	-6.9%	-10.5%	-6.3%
Mar 28	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$6.29	$5.93	-5.7%	-3.0%	-7.9%	-20.2%	-12.7%	-7.8%
Feb 18	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$12.96	$4.17	-67.8%	-47.0%	-57.2%	-54.6%	-55.2%	-55.8%
Feb 11	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$13.17	$12.97	-1.5%	-13.6%	-14.0%	-12.3%	-1.6%	-47.8%

Data updated apr 27, 2026 12:45am · Source: massive.com